Haynes and Boone represented Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, in a registered direct offering with certain healthcare-focused institutional investors for the sale of 20,000,000 shares of its common stock for gross proceeds of $40,000,000. H.C. Wainwright & Co. acted as the exclusive placement agent for the registered direct offering.
Pulmatrix Registered Direct Offering
Matthew L. Fry
Partner | Chair | Capital Markets and Securities Practice GroupT +1 214.651.5443 Email
Rick A. Werner
Partner | Co-chair - Capital Markets and Securities Practice GroupT +1 212.659.4974 Email